How much improvement is needed for a real difference of lower urinary tract symptoms after long‐term combination therapy for benign prostatic hyperplasia

Medical treatment is the first choice in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). This retrospective study investigated the changes of measured parameters after 4‐year medical therapy based on the reported quality of life index (QoL‐I) in the International Prostate Symptom Score (IPSS) questionnaire.

[1]  G. Pappagallo,et al.  Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.it , 2012, Therapeutic advances in urology.

[2]  T. Sugihara,et al.  Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score , 2012, BJU international.

[3]  A. Tubaro.  ASSESSMENT OF LOWER URINARY TRACT SYMPTOMS IN MEN BY INTERNATIONAL PROSTATE SYMPTOM SCORE AND CORE LOWER URINARY TRACT SYMPTOM SCORE , 2012, BJU international.

[4]  M. Rouprêt,et al.  Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia , 2011, World Journal of Urology.

[5]  S. Kaplan,et al.  Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. , 2011, The Journal of urology.

[6]  C. Roehrborn,et al.  Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4‐year results from the randomized, double‐blind Combination of Avodart and Tamsulosin (CombAT) trial , 2011, BJU international.

[7]  F. Montorsi,et al.  Effect of dutasteride, tamsulosin and the combination on patient‐reported quality of life and treatment satisfaction in men with moderate‐to‐severe benign prostatic hyperplasia: 4‐year data from the CombAT study , 2010, International journal of clinical practice.

[8]  M. Oelke,et al.  Current status of 5α-reductase inhibitors in the management of lower urinary tract symptoms and BPH , 2009, World Journal of Urology.

[9]  C. Roehrborn,et al.  The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. , 2009, European urology.

[10]  K. McVary,et al.  The role of combination medical therapy in benign prostatic hyperplasia , 2008, International Journal of Impotence Research.

[11]  M. Emberton,et al.  Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials , 2008, BJU international.

[12]  C. Roehrborn,et al.  Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. , 2008, The Journal of urology.

[13]  M. Emberton,et al.  Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management , 2008, International journal of clinical practice.

[14]  C. Roehrborn,et al.  The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. , 2008, The Journal of urology.

[15]  H. Kuo.  Videourodynamic analysis of pathophysiology of men with both storage and voiding lower urinary tract symptoms. , 2007, Urology.

[16]  K. McVary.  A review of combination therapy in patients with benign prostatic hyperplasia. , 2007, Clinical therapeutics.

[17]  C. Roehrborn,et al.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. , 2003, The New England journal of medicine.

[18]  P. Boyle,et al.  Improvements in benign prostatic hyperplasia‐specific quality of life with dutasteride, the novel dual 5α‐reductase inhibitor , 2003, BJU international.

[19]  W. Stewart,et al.  Prevalence and burden of overactive bladder in the United States , 2003, World Journal of Urology.

[20]  P. Boyle,et al.  Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. , 2002, Urology.

[21]  J. Blaivas,et al.  Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. , 2001, The Journal of urology.

[22]  S. Akimoto,et al.  The natural history of benign prostatic hyperplasia. , 1997, Harvard men's health watch.

[23]  W. Hop,et al.  Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. , 1995, Urology.

[24]  W. Hop,et al.  The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. , 1995, British journal of urology.

[25]  M. Barry,et al.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.

[26]  C. Roehrborn,et al.  The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. , 2010, European urology.

[27]  J. Batista-Miranda,et al.  Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions. , 2001, PharmacoEconomics.

[28]  D. Skinner.  Management of extensive, localized neoplasms of lower abdominal wall. Pubectomy and scrotal skin transfer technique. , 1974, Urology.